Colorectal cancer cells reprogram their fat metabolism to fuel tumor growth and escape immune system attacks, according to Gram Research analysis of current oncology literature. Research shows that cancer cells increase their uptake and production of fats through proteins like CD36 and FASN, which simultaneously promote tumor progression and suppress immune function. Blocking these fat metabolism proteins combined with immunotherapy or chemotherapy represents a promising strategy to overcome treatment resistance, though these combination approaches are still experimental and not yet standard care.
Colorectal cancer cells have learned a clever trick: they reprogram their metabolism to consume and produce more fat, which helps them grow faster and escape the immune system’s attacks. According to Gram Research analysis, this fat-focused metabolism also makes tumors resistant to chemotherapy and immunotherapy. Scientists have identified specific proteins that control this fat metabolism in cancer cells, including CD36, FASN, ACC, and SCD1. The exciting news is that blocking these proteins could stop cancer cells from using fat as their shield, and combining these blockers with existing cancer treatments might finally overcome treatment resistance that currently limits patient survival.
Key Statistics
A 2026 review in Critical Reviews in Oncology/Hematology identified four key proteins (CD36, FASN, ACC, and SCD1) that control lipid metabolic reprogramming in colorectal cancer cells, with inhibiting these proteins offering dual therapeutic advantages against tumor growth and immune escape.
Research shows that colorectal cancer cells actively reprogram their metabolism to increase lipid uptake and de novo synthesis, creating an immunosuppressive microenvironment that promotes both tumor proliferation and resistance to chemotherapy and checkpoint inhibitor immunotherapies.
According to a comprehensive review of lipid metabolism in colorectal cancer, combining metabolic inhibitors with immune checkpoint inhibitors, chemotherapies, or targeted therapeutics represents a promising strategy for circumventing treatment resistance in patients whose tumors have become resistant to standard approaches.
The Quick Take
- What they studied: How colorectal cancer cells change their fat metabolism to survive treatment and hide from the immune system
- Who participated: This was a comprehensive review of existing research on lipid metabolism in colorectal cancer, not a study with human participants
- Key finding: Cancer cells deliberately increase their fat uptake and production, which fuels tumor growth and creates an environment where the immune system cannot attack the cancer effectively
- What it means for you: New treatment strategies that block cancer cells’ ability to use fat, combined with existing immunotherapy drugs, could help patients whose cancers have become resistant to current treatments. However, these approaches are still in research stages and not yet available as standard care
The Research Details
This was a comprehensive review article, meaning researchers analyzed and summarized findings from many existing studies on lipid metabolism in colorectal cancer rather than conducting their own experiment. The authors examined how cancer cells reprogram their metabolism, focusing on the role of fat (lipids) in tumor growth and treatment resistance. They looked at the molecular mechanisms, the immune system’s role, and potential therapeutic strategies. This type of review is valuable because it synthesizes current knowledge and identifies patterns across multiple studies, helping scientists understand the big picture of how cancer uses fat metabolism.
Understanding the mechanisms behind treatment resistance is critical because many colorectal cancer patients develop tumors that stop responding to chemotherapy and immunotherapy. By identifying that fat metabolism is a central hub controlling both tumor growth and immune escape, researchers can design new drugs that target this vulnerability. A review approach is important here because it allows experts to connect findings from different labs and identify the most promising therapeutic targets without waiting for new experiments.
This review was published in a peer-reviewed oncology journal, meaning it underwent expert scrutiny. The authors synthesized evidence from multiple studies rather than relying on single experiments. However, as a review article, it does not present original experimental data. The strength lies in identifying patterns and connections across existing research. Readers should understand that while the mechanisms described are supported by multiple studies, the proposed combination therapies are still largely experimental and require clinical trials before becoming standard treatment
What the Results Show
Cancer cells actively reprogram their metabolism to increase fat uptake and production. This metabolic shift serves multiple purposes: it provides energy and building blocks for rapid tumor growth, and it creates an immunosuppressive environment where immune cells cannot effectively attack the cancer. Key proteins controlling this process include CD36 (which helps cells absorb fat), FASN (which helps cells make fat), ACC (which regulates fat production), and SCD1 (which modifies fat structure). These proteins are overactive in colorectal cancer cells and promote both tumor progression and resistance to treatment. The review emphasizes that this is not a passive consequence of cancer but an active strategy that cancer cells use to survive. By understanding these mechanisms, researchers identified that blocking these proteins could have a dual benefit: directly slowing tumor growth while also restoring the immune system’s ability to fight cancer.
The review highlights that lipid metabolic reprogramming remodels the tumor microenvironment, the tissue surrounding the cancer. This remodeling includes changes that suppress immune cell function and promote the survival of cancer cells. The authors note that this metabolic reprogramming is a major driver of therapeutic resistance, explaining why some patients’ cancers stop responding to chemotherapy and immunotherapy. Additionally, the review suggests that different colorectal cancers may rely on different aspects of lipid metabolism, which could explain tumor heterogeneity and why single-drug treatments often fail. This finding supports the need for personalized medicine approaches that identify which metabolic pathways are most active in each patient’s tumor.
This review builds on growing evidence that cancer cells fundamentally reprogram their metabolism to survive. Previous research established that cancer cells use glucose differently than normal cells, a concept known as the Warburg effect. This review extends that understanding by showing that lipid metabolism is equally important, if not more so, in colorectal cancer specifically. The authors note that while metabolic inhibitors have been studied for years, the key innovation is combining them with immunotherapy and targeted drugs. This combination approach represents a shift from trying to kill cancer cells alone to simultaneously killing cancer cells and restoring immune function. The review also connects lipid metabolism to immune escape, a relatively newer understanding that explains why some patients develop resistance to checkpoint inhibitor immunotherapies.
As a review article, this work does not present new experimental data, so readers cannot assess the methodology of original studies in detail. The review synthesizes findings from multiple studies that may have used different methods and patient populations, which can make it difficult to draw definitive conclusions. Most of the proposed combination therapies discussed are still in preclinical or early clinical stages, meaning they have not been proven safe and effective in large patient populations. The review focuses on mechanisms and potential approaches rather than established clinical guidelines. Additionally, the authors note that colorectal cancer is heterogeneous, meaning different tumors may respond differently to metabolic inhibitors, so a one-size-fits-all approach is unlikely to work for all patients
The Bottom Line
Current evidence suggests that targeting lipid metabolism proteins (CD36, FASN, ACC, SCD1) combined with existing cancer treatments is a promising research direction. However, these approaches are not yet standard care. Patients with colorectal cancer should continue following their oncologist’s recommendations for proven treatments like chemotherapy, immunotherapy, and surgery. Those interested in metabolic approaches should ask their doctor about clinical trials testing combination therapies. Confidence level: Moderate for the basic mechanisms described, but low for clinical application since most combination therapies are still experimental
This research is most relevant to colorectal cancer patients, especially those whose tumors have become resistant to standard treatments. Oncologists and cancer researchers should be aware of these mechanisms when designing treatment plans and clinical trials. Patients with a family history of colorectal cancer may find this information relevant for understanding disease biology. This research is not directly applicable to people without cancer, though some findings about metabolic health may have broader implications being studied elsewhere. Patients should not attempt to modify their diet or take supplements based on this review without consulting their oncologist, as the mechanisms described do not translate directly to dietary recommendations
If metabolic inhibitors combined with immunotherapy prove effective in ongoing clinical trials, it could take 3 to 5 years before such treatments become available to patients outside of trials. Individual responses vary significantly, so some patients might see benefits within weeks while others might take months. The timeline for seeing benefits depends on the specific combination therapy, the patient’s tumor characteristics, and how quickly the cancer responds. Realistic expectations are important: even effective new treatments typically slow cancer progression rather than eliminate it completely, and benefits must be weighed against potential side effects
Frequently Asked Questions
Why do cancer cells use so much fat and what does it do for them?
Cancer cells reprogram their metabolism to consume and produce excess fat because it provides energy for rapid growth and materials to build new cell membranes. Additionally, this fat metabolism creates an environment that suppresses immune cells, allowing cancer to hide from the body’s natural defenses and resist treatment.
Can blocking fat metabolism stop colorectal cancer from coming back?
Blocking fat metabolism proteins shows promise in research, but it is not yet proven to prevent cancer recurrence in patients. Combining metabolic inhibitors with existing treatments like immunotherapy may improve outcomes, but these approaches are still experimental and require clinical trials to establish safety and effectiveness.
What should I eat if I have colorectal cancer to affect its fat metabolism?
This review does not provide specific dietary recommendations because the fat metabolism mechanisms described are cellular processes that cannot be directly controlled by diet alone. Patients with colorectal cancer should follow their oncologist’s nutritional guidance and ask about clinical trials testing metabolic approaches before making dietary changes.
How soon could these new fat-blocking treatments be available to patients?
Most combination therapies targeting lipid metabolism are still in preclinical or early clinical trial stages. If trials are successful, it could take 3 to 5 years before such treatments become widely available. Interested patients should ask their oncologist about enrollment in clinical trials testing these approaches.
Does this research apply to other types of cancer besides colorectal cancer?
This review focuses specifically on colorectal cancer, though lipid metabolic reprogramming occurs in many cancer types. Other cancers may rely on different metabolic pathways or use lipid metabolism differently, so findings from colorectal cancer research may not directly apply to breast cancer, lung cancer, or other malignancies.
Want to Apply This Research?
- If a user is enrolled in a clinical trial testing metabolic inhibitors, they could track weekly energy levels, appetite changes, and any gastrointestinal symptoms using a simple 1-10 scale. This helps identify patterns and side effects that should be reported to their oncology team
- Users interested in metabolic health could track their intake of omega-3 fatty acids and processed fats, as emerging research suggests diet composition may influence tumor metabolism. However, this should only be done under oncologist guidance, as specific dietary changes during cancer treatment require professional oversight
- Long-term tracking should focus on treatment response markers that the oncology team monitors, such as tumor size on imaging scans and blood tumor markers. Users can maintain a simple log of treatment dates, side effects, and clinical visit results to share with their care team and identify patterns over months and years
This article summarizes research on lipid metabolism in colorectal cancer and should not be interpreted as medical advice. The mechanisms and combination therapies described are based on current research but are not yet standard clinical practice. Patients with colorectal cancer should continue following their oncologist’s treatment recommendations and discuss any interest in metabolic approaches or clinical trials with their care team. Do not modify diet, supplements, or treatment based on this information without consulting your physician. This review does not replace professional medical diagnosis or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.